The Challenges of Monitoring Glycemic Control in Patients with Chronic Kidney Disease Using A1c

Accurate glycemic monitoring is essential for managing diabetes, but in patients with chronic kidney disease (CKD), the standard Hemoglobin A1c (A1c) test can be unreliable. Kidney disease alters red blood cell physiology, introduces treatment-related variables, and changes the underlying relationship between blood glucose and glycated hemoglobin. Clinicians who rely solely on A1c risk misinterpreting glycemic control—leading to overtreatment or undertreatment. This article explores why A1c struggles in CKD, evaluates alternative monitoring tools, and provides practical guidance for clinical decision-making, integrating the latest evidence and consensus recommendations.

Why A1c Fails in Chronic Kidney Disease

The A1c test measures the percentage of hemoglobin A that is glycated, reflecting average plasma glucose over the preceding 8–12 weeks. The test assumes a normal red blood cell lifespan of approximately 120 days. In CKD, multiple pathophysiologic changes break this assumption, making the standard equation unreliable.

Anemia of CKD and Red Blood Cell Lifespan

Anemia is nearly universal in advanced CKD (stages 3b–5). Decreased erythropoietin production, iron deficiency, and chronic inflammation reduce hemoglobin levels. Red blood cells (RBCs) in CKD have a shortened lifespan, often 60–90 days instead of 120. Because A1c accumulates over the RBC's life, a shorter lifespan means less time for glucose to bind, producing a falsely low A1c relative to true glycemic exposure. Studies have demonstrated that mean A1c can underestimate average glucose by 0.5–1 percentage point in anemic CKD patients, an effect that worsens as hemoglobin drops below 10 g/dL. The difference becomes especially pronounced in patients with hemoglobin less than 9 g/dL.

Erythropoietin-Stimulating Agents (ESAs)

Patients on erythropoietin therapy receive a surge of young RBCs with less prior glycation. This influx further dilutes glycated hemoglobin, driving A1c downward. The effect is most pronounced in the first weeks after dosing, with A1c often declining by 0.5–1.0% despite stable or even increasing glucose levels. For example, a patient whose A1c drops from 7.5% to 6.8% after starting ESAs may actually have worsening hyperglycemia. The disconnect persists for the lifespan of the new RBCs, meaning A1c may not reflect steady-state glycemia for up to three months after a dose change. This artefact can mislead clinicians into reducing diabetes medications unnecessarily, risking hypoglycemia.

Iron Deficiency and Hemoglobin Glycation

Iron deficiency, common in CKD, impairs hemoglobin synthesis. Altered hemoglobin structure can affect the rate of glycation. Moreover, iron therapy corrects anemia and changes RBC turnover, temporarily distorting A1c. Even without overt anemia, subclinical iron deficiency influences results. In the setting of oral or intravenous iron administration, reticulocytosis increases the fraction of young RBCs, further lowering A1c independently of glucose. This transient effect can persist for 2–4 weeks after treatment, complicating interpretation of follow-up labs.

Uremia and Carbamylated Hemoglobin

Urea accumulates in the bloodstream of CKD patients. Excess urea leads to the formation of carbamylated hemoglobin, which is chemically similar to glycated hemoglobin. Some A1c assays cannot distinguish between the two, yielding a falsely elevated result. This interference varies by assay method: ion-exchange high-performance liquid chromatography (HPLC) is more susceptible to carbamylated hemoglobin interference, while immunoassays may be less affected but still vulnerable. Laboratories should report the assay type used; clinicians must be aware that a patient on hemodialysis with a urea reduction ratio less than 65% may have particularly large carbamylation effects. The net effect can be an A1c that is 0.3–0.7% higher than the true glycemic value.

Kidney Transplant and Dialysis Effects

After kidney transplantation, immunosuppressive medications (corticosteroids, calcineurin inhibitors) can raise blood glucose while A1c may lag behind due to persistent anemia and ESA use. New-onset diabetes after transplantation (NODAT) is common, and reliance on A1c alone can delay diagnosis. Conversely, during hemodialysis, A1c can be lowered by dialysate-induced hemolysis or improved erythropoiesis. The dialyzer itself may remove small fragments of hemoglobin, further distorting the measurement. Peritoneal dialysis introduces glucose absorption from dialysate, often causing hyperglycemia that may not be fully captured by A1c because of the same hematologic confounders. Fluid shifts during dialysis sessions can also cause transient changes in glucose readings, making spot fingerstick tests less reliable.

Consequences of Relying on A1c Alone in CKD

Using A1c as the sole metric leads to two clinical hazards:

  • Underestimation of hyperglycemia – A falsely low A1c can lead to failure to intensify therapy, worsening glycemic control and increasing the risk of microvascular complications such as retinopathy, neuropathy, and progression of CKD itself. The U-shaped relationship between A1c and mortality in dialysis patients may partly reflect this artifact.
  • Overestimation of hyperglycemia (or hypoglycemia) – In contrast, when carbamylated hemoglobin elevates A1c, clinicians may assume poor control and intensify therapy inappropriately, precipitating severe hypoglycemic events. Hypoglycemia in CKD is especially dangerous due to reduced renal gluconeogenesis and impaired counter-regulation.

Both scenarios increase morbidity and mortality. In a study of over 10,000 patients with stage 4–5 CKD, the discordance between A1c and measured glucose profiles was found to be as high as 30%, underscoring the need for complementary tests.

Alternative and Complementary Monitoring Strategies

Fructosamine Test

Fructosamine measures glycated serum proteins, primarily albumin. It reflects glucose control over 2–3 weeks, the half-life of albumin. Because it does not depend on red blood cell lifespan, it avoids the major confounders of A1c in CKD. Fructosamine is minimally affected by anemia, iron status, or ESA use. However, hypoalbuminemia (common in nephrotic-range proteinuria or malnutrition) lowers fructosamine values. When albumin is below 3.0 g/dL, results may be unreliable. Serial fructosamine measurements can still trend glycemia effectively, provided albumin remains stable. In practice, many laboratories report fructosamine values adjusted for albumin concentration, though standardization remains imperfect. Despite these limitations, fructosamine is inexpensive and widely available, making it a practical first-line alternative in many nephrology clinics.

Glycated Albumin (GA)

Glycated albumin is a more specific measure than total fructosamine. It reports the percentage of albumin that is glycated, correcting for albumin concentration. GA correlates well with mean glucose over 2–3 weeks and is not influenced by hemoglobin turnover. In CKD, GA has been shown to align with continuous glucose monitoring (CGM) data more closely than A1c. A meta-analysis found that GA had a correlation coefficient of 0.75–0.85 with mean glucose in CKD stages 4–5, compared to 0.55–0.65 for A1c. The main limitation is cost and limited availability in some settings. GA may also be lower in severe obesity and higher in insulin resistance, although these effects are modest. Some guidelines now suggest GA as a preferred test in dialysis patients, especially when CGM is not accessible.

Continuous Glucose Monitoring (CGM)

CGM provides real-time interstitial glucose readings and time-in-range (TIR) data. TIR reflects the percentage of time glucose is within 70–180 mg/dL. CGM bypasses all hemoglobin- and protein-based artifacts. It detects both hyperglycemia and hypoglycemia without relying on red blood cells. In CKD patients, CGM can uncover nocturnal hypoglycemia that A1c and even fingerstick testing might miss. The 2024 KDIGO guidelines recommend CGM as a preferred tool in CKD stage 4–5 and dialysis-dependent patients. Studies have shown that CGM use reduces hypoglycemic events by up to 50% in insulin-treated CKD patients. Barriers include patient access, insurance coverage, and the need for training. Nonetheless, CGM is rapidly becoming the gold standard in this population. For patients who cannot use real-time CGM, professional CGM (blinded or unblinded) can be worn for 10–14 days to capture glycemic patterns without requiring the patient to own a device.

Self-Monitoring of Blood Glucose (SMBG)

Regular fingerstick testing remains widely available and inexpensive. SMBG provides immediate data for medication adjustments and lifestyle modifications. In CKD, patients on insulin or secretagogues benefit from structured SMBG (e.g., 4–7 times/day). However, SMBG only captures snapshots, not the full glucose profile. It should be combined with a longer-term measure like fructosamine, glycated albumin, or CGM time-in-range. For patients on hemodialysis, timing of SMBG matters: readings taken immediately before or during dialysis may differ due to fluid shifts and hemoconcentration. Clinicians should instruct patients to measure glucose at consistent times relative to meals and dialysis sessions.

1,5-Anhydroglucitol (1,5-AG)

1,5-AG reflects postprandial hyperglycemia over the prior 1–2 weeks. It works by a renal competition mechanism with glucose, which is problematic in CKD because renal function itself affects the test. Currently, 1,5-AG is not recommended for CKD patients due to unreliable results in impaired kidney function. Research into modified algorithms is ongoing, but for now, it is not a practical alternative.

Clinical Considerations and Best Practices

Individualize Target Ranges

Glycemic targets in CKD should account for kidney function, comorbidities, frailty, and hypoglycemia risk. The ADA recommends a general A1c target of <7% (53 mmol/mol), but in CKD with reduced life expectancy or high hypoglycemia risk, targets of <8% (64 mmol/mol) are appropriate. When A1c is unreliable, use a target of >50% time-in-range (70–180 mg/dL) or keep fasting/pre-meal glucose 100–140 mg/dL. For patients on peritoneal dialysis, targeting a fasting glucose below 140 mg/dL may be more practical than any A1c goal. In older or frail patients, avoiding hypoglycemia takes priority over achieving strict glucose targets.

Use Multiple Methods and Trend Analysis

No single test is perfect. A pragmatic strategy is:

  • Measure A1c quarterly but always interpret it in the context of hematologic status (hemoglobin, reticulocyte count, ESA dose, iron indices). Request the laboratory to note the assay method and any known interferences.
  • If A1c is discordant with clinical judgment (e.g., a low A1c in a patient with high SMBG readings), order a fructosamine or glycated albumin test. Trending these over time is more helpful than a single value.
  • Encourage SMBG with structured testing, and where possible, initiate CGM—particularly in patients with insulin regimens or a history of hypoglycemia, or those who are candidates for glycemic optimization before transplant.
  • Use the concept of "glycemic gap" (the difference between measured glucose and A1c-predicted average glucose) to prompt further investigation.

Adjust Monitoring Frequency in CKD Stages

  • CKD stage 3a-b: A1c remains moderately reliable if hemoglobin >10 g/dL and no ESA use. Check A1c every 3 months with confirmatory SMBG twice daily. If hemoglobin drops below 10, consider adding fructosamine.
  • CKD stage 4–5 (non-dialysis): Add fructosamine or glycated albumin every 3 months; consider CGM at least once a year. Avoid relying solely on A1c.
  • Hemodialysis: Fructosamine or glycated albumin preferred. Avoid A1c days after dialysis when RBC lifespan is most distorted. CGM is particularly useful in this population to detect dialysis-associated hypoglycemia and glycemic excursions.
  • Peritoneal dialysis: CGM preferred due to glucose load from dialysate. Fructosamine can be used but watch for hypoalbuminemia. Consider measuring A1c only as a supplementary check, with full awareness of its limitations.

Educate Patients and Care Teams

Patients should understand that their A1c may not accurately reflect their blood sugar. Explain why the doctor may order additional tests. Provide teach-back: "I want you to know that because your kidneys are not working at full strength, the A1c test can sometimes be wrong. That's why I'm also checking your average sugar with a different blood test and asking you to check your sugar at home." Encourage consistent SMBG and logging of hypoglycemic events. For patients on dialysis, coordinate with nephrologists to time A1c measurements to the longest interval after ESA dosing. Fluid shifts during HD can also affect fingerstick readings; CGM mitigates this. In programs that do not have CGM available, a combined approach with fructosamine and SMBG is acceptable.

Medication Adjustments Based on Real Data

Using CGM or fructosamine, clinicians can more safely titrate insulin and sulfonylureas. In patients with a falsely low A1c, actual glucose may be higher than reflected; consider increasing therapy only if SMBG/CGM or fructosamine supports it. Conversely, if A1c is falsely elevated due to carbamylated hemoglobin, avoid unnecessary intensification that could cause hypoglycemia. In patients on hemodialysis, insulin clearance is reduced, so lower total daily insulin doses are often needed; using CGM data can help avoid overinsulinization. For metformin, use is limited by kidney function (contraindicated when eGFR <30), but when used in stage 3, it rarely causes hypoglycemia and may not require frequent adjustment based on monitoring artifacts.

Future Directions

Newer markers like 1,5-anhydroglucitol (1,5-AG) reflect postprandial hyperglycemia over days, but its reliability in CKD is still under investigation. Glycated albumin-to-A1c ratio is being studied as a way to detect discordance—a ratio above certain thresholds may indicate A1c is falsely low or high. The ADAG (A1c-Derived Average Glucose) equation does not validate in CKD; none of the standard conversion formulas apply. Continued research into CKD-specific algorithms is needed, and some investigators are exploring machine learning models that integrate A1c, fructosamine, hemoglobin, and ESA doses to estimate true mean glucose. Point-of-care CGM devices suitable for the dialysis unit are in development, which could make real-time glucose data available at the chairside. For now, the most practical roadmap for clinicians is to use multiple metrics and interpret trends with a healthy skepticism of any single number.

Conclusion and Practical Checklist

Monitoring glycemic control in CKD demands a shift from A1c-centric to multi-metric vigilance. A1c is not obsolete but must be interpreted with full awareness of its limitations. The best approach combines A1c, a short-term protein glycation test, and SMBG or CGM. Individualized targets, patient education, and coordination between endocrinology and nephrology teams are essential. Consider the following checklist for your clinical practice:

  • At each visit, review A1c together with hemoglobin, iron indices, ESA dose, and albumin.
  • If discordance is suspected (e.g., Hb <10, recent ESA, dialysis, or extremes of glucose by SMBG), order a fructosamine or glycated albumin test.
  • For insulin-treated patients or those with hypoglycemia unawareness, prescribe CGM or arrange professional CGM periodically.
  • Individualize glycemic targets: time-in-range >50% (70–180 mg/dL), avoid glucose <70 mg/dL, and tailor A1c goals to the patient's stage and risk profile.
  • Educate patients that A1c may be inaccurate and teach them to rely on self-monitoring and symptoms as primary guides.
  • Document the monitoring plan clearly in the chart, including which tests were used and why.

For further reading, consult the KDIGO 2024 Clinical Practice Guideline for Diabetes Management in CKD, the ADA Standards of Care Chapter on Diabetes and CKD, and the NIDDK overview of diabetes tests. Additional evidence supporting CGM use in CKD can be found in the 2022 meta-analysis on CGM in chronic kidney disease.